We thank Dr Jens Y. Humrich and Dr Gabriela Riemekasten for their interest in our study 1 , which they discussed in a News & Views commentary (Humrich, J. Y. & Riemekasten, G. The rise of IL-2 therapy -a novel biologic treatment for SLE. Nat. Rev. Rheumatol. 12, 695-696; 2016) 2 . We are particularly excited that more clinical and basic scientists are working to understand the mechanisms of action underpinning the promising 'experimental medicine' observations of low-dose IL-2 therapy in systemic lupus erythematosus (SLE). After reading the commentary, however, we noted that there was a misunderstanding of the research design of our study. We hereby provide further clarification.
The inspiration for this study of lowdose IL-2 therapy in autoimmune diseases came from our previous publication showing that hyperactivation of follicular helper T (T FH ) cells correlated with disease activity in patients with SLE and rheumatoid arthritis 3 ; this is a different focus from the studies of low-dose IL-2 therapy, which centred on regulatory T (T reg ) cells [4] [5] [6] . Although IL-2 had been shown to suppress T FH and type 17 T helper (T H 17) cells in mouse models 7, 8 , its effects in human cells were unknown. We started our study in 2013, with clinical responses as the primary end point and an emphasis on immuno logical responses, including changes in T FH , T H 17 and T reg cells, as secondary end points 9 . For the first time, we demonstrated that low-dose IL-2 therapy could suppress T FH and T H 17 cells in humans 1 . In addition, using a mouse model, we revealed that suppression of T FH and T H 17 cells was as sensitive to low-dose IL-2 as the promotion of T reg cells. During the peer review process, we were asked to exclude the possibility that the increase in T reg cells and decreases in T FH and T H 17 cells accompanying low-dose IL-2 administration were a consequence of significantly lowered disease activity. Therefore, we analysed the immunological phenotype in another, separate cohort of patients who underwent a comparable response under conventional immunosuppressive treatments, and found no such changes in T reg , T FH and T H 17 cells. This separate cohort was not a placebo-control group and we agree with the proposal of Drs Humrich and Riemekasten that a parallel study would be ideal.
Our . Owing to the limitations of the available phenotypical markers used to characterise T reg cells, we also performed a standard suppressive assay showing that low-dose IL-2 treatment in mice and humans promoted the suppressive function of T reg cells 1 . SLE is a very complex and poorly treated disease. As low-dose IL-2 emerges as a new therapy for this disease, we agree that more studies, including well-controlled randomized trials, will be needed to understand the underlying mechanisms, optimise treatment regimens and select the most suitable patients. These important follow-up studies are currently underway.
